PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-65.77%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-6.04%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-65.74%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-47.67%
Negative EPS growth while AVXL is at 27.27%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-53.82%
Negative diluted EPS growth while AVXL is at 27.27%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
12.14%
Share reduction more than 1.5x AVXL's 77.91%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
7.50%
Diluted share reduction more than 1.5x AVXL's 77.91%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-13.29%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-13.04%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24856.69%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-19589.97%
Negative 5Y OCF/share CAGR while AVXL is at 84.61%. Joel Greenblatt would question the firm’s operational model or cost structure.
63.13%
Positive 3Y OCF/share CAGR while AVXL is negative. John Neff might see a big short-term edge in operational efficiency.
-19587.84%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-19245.92%
Negative 5Y net income/share CAGR while AVXL is 65.72%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
62.10%
Positive short-term CAGR while AVXL is negative. John Neff would see a clear advantage in near-term profit trajectory.
30196.53%
10Y equity/share CAGR above 1.5x AVXL's 7055.51%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
5954.03%
5Y equity/share CAGR above 1.5x AVXL's 177.27%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
827.17%
3Y equity/share CAGR above 1.5x AVXL's 199.14%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.14%
Asset growth well under 50% of AVXL's 92.34%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-14.41%
We have a declining book value while AVXL shows 2.50%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-8.17%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
28.86%
SG&A declining or stable vs. AVXL's 351.33%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.